They were essentially forced to pivot to inhaled formulation because the IV dose went straight to the liver
Glad to see the two new indications are still on track to be announced by end of this year.
- Forums
- ASX - By Stock
- 1AD
- Ann: AD-214 pathway to IPF efficacy studies
1AD
adalta limited
Add to My Watchlist
0.00%
!
0.2¢

Ann: AD-214 pathway to IPF efficacy studies, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.142M |
Open | High | Low | Value | Volume |
0.2¢ | 0.2¢ | 0.2¢ | $4.365K | 2.182M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
27 | 23729304 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 9592565 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 23729304 | 0.002 |
15 | 40453497 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 9592565 | 17 |
0.004 | 13062108 | 11 |
0.005 | 2946002 | 7 |
0.006 | 1963830 | 1 |
0.007 | 133335 | 1 |
Last trade - 12.32pm 25/06/2025 (20 minute delay) ? |
Featured News
1AD (ASX) Chart |